Literature DB >> 28650484

Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.

Sjors M Kas1, Julian R de Ruiter1,2, Koen Schipper1, Stefano Annunziato1, Eva Schut1, Sjoerd Klarenbeek3, Anne Paulien Drenth1, Eline van der Burg1, Christiaan Klijn1, Jelle J Ten Hoeve2, David J Adams4, Marco J Koudijs1, Jelle Wesseling1,5, Micha Nethe1, Lodewyk F A Wessels2,6,7, Jos Jonkers1,6.   

Abstract

Invasive lobular carcinoma (ILC) is the second most common breast cancer subtype and accounts for 8-14% of all cases. Although the majority of human ILCs are characterized by the functional loss of E-cadherin (encoded by CDH1), inactivation of Cdh1 does not predispose mice to develop mammary tumors, implying that mutations in additional genes are required for ILC formation in mice. To identify these genes, we performed an insertional mutagenesis screen using the Sleeping Beauty transposon system in mice with mammary-specific inactivation of Cdh1. These mice developed multiple independent mammary tumors of which the majority resembled human ILC in terms of morphology and gene expression. Recurrent and mutually exclusive transposon insertions were identified in Myh9, Ppp1r12a, Ppp1r12b and Trp53bp2, whose products have been implicated in the regulation of the actin cytoskeleton. Notably, MYH9, PPP1R12B and TP53BP2 were also frequently aberrated in human ILC, highlighting these genes as drivers of a novel oncogenic pathway underlying ILC development.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28650484     DOI: 10.1038/ng.3905

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  63 in total

Review 1.  Molecular components of the adherens junction.

Authors:  Carien M Niessen; Cara J Gottardi
Journal:  Biochim Biophys Acta       Date:  2008-01-14

2.  Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse.

Authors:  Lara S Collier; Corey M Carlson; Shruthi Ravimohan; Adam J Dupuy; David A Largaespada
Journal:  Nature       Date:  2005-07-14       Impact factor: 49.962

3.  High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer.

Authors:  Daniel E Stange; Bernhard Radlwimmer; Falk Schubert; Frank Traub; Andreas Pich; Grischa Toedt; Frank Mendrzyk; Ulrich Lehmann; Roland Eils; Hans Kreipe; Peter Lichter
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

4.  Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas.

Authors:  Daniel Schramek; Ataman Sendoel; Jeremy P Segal; Slobodan Beronja; Evan Heller; Daniel Oristian; Boris Reva; Elaine Fuchs
Journal:  Science       Date:  2014-01-17       Impact factor: 47.728

5.  Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.

Authors:  R Moll; M Mitze; U H Frixen; W Birchmeier
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

6.  Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.

Authors:  Linda Henneman; Martine H van Miltenburg; Ewa M Michalak; Tanya M Braumuller; Janneke E Jaspers; Anne Paulien Drenth; Renske de Korte-Grimmerink; Ewa Gogola; Karoly Szuhai; Andreas Schlicker; Rahmen Bin Ali; Colin Pritchard; Ivo J Huijbers; Anton Berns; Sven Rottenberg; Jos Jonkers
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-22       Impact factor: 11.205

7.  FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas.

Authors:  Jorge Sergio Reis-Filho; Pete T Simpson; Nicholas C Turner; Maryou Ballo Lambros; Chris Jones; Alan Mackay; Anita Grigoriadis; David Sarrio; Kay Savage; Tim Dexter; Marjan Iravani; Kerry Fenwick; Barbara Weber; David Hardisson; Fernando Carlos Schmitt; Jose Palacios; Sunil R Lakhani; Alan Ashworth
Journal:  Clin Cancer Res       Date:  2006-11-15       Impact factor: 12.531

8.  Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

Authors:  Magali Michaut; Suet-Feung Chin; Ian Majewski; Tesa M Severson; Tycho Bismeijer; Leanne de Koning; Justine K Peeters; Philip C Schouten; Oscar M Rueda; Astrid J Bosma; Finbarr Tarrant; Yue Fan; Beilei He; Zheng Xue; Lorenza Mittempergher; Roelof J C Kluin; Jeroen Heijmans; Mireille Snel; Bernard Pereira; Andreas Schlicker; Elena Provenzano; Hamid Raza Ali; Alexander Gaber; Gillian O'Hurley; Sophie Lehn; Jettie J F Muris; Jelle Wesseling; Elaine Kay; Stephen John Sammut; Helen A Bardwell; Aurélie S Barbet; Floriane Bard; Caroline Lecerf; Darran P O'Connor; Daniël J Vis; Cyril H Benes; Ultan McDermott; Mathew J Garnett; Iris M Simon; Karin Jirström; Thierry Dubois; Sabine C Linn; William M Gallagher; Lodewyk F A Wessels; Carlos Caldas; Rene Bernards
Journal:  Sci Rep       Date:  2016-01-05       Impact factor: 4.379

9.  E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis.

Authors:  C B Vos; A M Cleton-Jansen; G Berx; W J de Leeuw; N T ter Haar; F van Roy; C J Cornelisse; J L Peterse; M J van de Vijver
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  ASPP1/2-PP1 complexes are required for chromosome segregation and kinetochore-microtubule attachments.

Authors:  Pingzhao Zhang; Yuanyuan Zhang; Kun Gao; Yuqi Wang; Xiaofeng Jin; Youheng Wei; Heige Saiyin; Dejie Wang; Jintao Peng; Jian Ma; Yan Tang; Reziya Wumaier; Hongxiu Yu; Yimin Dong; Haojie Huang; Long Yu; Chenji Wang
Journal:  Oncotarget       Date:  2015-12-08
View more
  33 in total

Review 1.  RUNX1-dependent mechanisms in biological control and dysregulation in cancer.

Authors:  Deli Hong; Andrew J Fritz; Jonathan A Gordon; Coralee E Tye; Joseph R Boyd; Kirsten M Tracy; Seth E Frietze; Frances E Carr; Jeffrey A Nickerson; Andre J Van Wijnen; Anthony N Imbalzano; Sayyed K Zaidi; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2018-12-04       Impact factor: 6.384

Review 2.  How to Choose a Mouse Model of Breast Cancer, a Genomic Perspective.

Authors:  Matthew R Swiatnicki; Eran R Andrechek
Journal:  J Mammary Gland Biol Neoplasia       Date:  2019-06-21       Impact factor: 2.673

Review 3.  In vivo functional screening for systems-level integrative cancer genomics.

Authors:  Julia Weber; Christian J Braun; Dieter Saur; Roland Rad
Journal:  Nat Rev Cancer       Date:  2020-07-07       Impact factor: 60.716

4.  In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.

Authors:  Stefano Annunziato; Catrin Lutz; Linda Henneman; Jinhyuk Bhin; Kim Wong; Bjørn Siteur; Bas van Gerwen; Renske de Korte-Grimmerink; Maria Paz Zafra; Emma M Schatoff; Anne Paulien Drenth; Eline van der Burg; Timo Eijkman; Siddhartha Mukherjee; Katharina Boroviak; Lodewyk Fa Wessels; Marieke van de Ven; Ivo J Huijbers; David J Adams; Lukas E Dow; Jos Jonkers
Journal:  EMBO J       Date:  2020-01-13       Impact factor: 11.598

Review 5.  MYH9: Structure, functions and role of non-muscle myosin IIA in human disease.

Authors:  Alessandro Pecci; Xuefei Ma; Anna Savoia; Robert S Adelstein
Journal:  Gene       Date:  2018-04-19       Impact factor: 3.688

6.  Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice.

Authors:  Lisette M Cornelissen; Linda Henneman; Anne Paulien Drenth; Eva Schut; Roebi de Bruijn; Sjoerd Klarenbeek; Wilbert Zwart; Jos Jonkers
Journal:  J Mammary Gland Biol Neoplasia       Date:  2019-11-15       Impact factor: 2.673

7.  Scinderin-knockdown inhibits proliferation and promotes apoptosis in human breast carcinoma cells.

Authors:  Wenjing Jian; Xiaoli Zhang; Jiguo Wang; Yunlong Liu; Chuting Hu; Xianming Wang; Renbin Liu
Journal:  Oncol Lett       Date:  2018-06-21       Impact factor: 2.967

8.  Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.

Authors:  Hillary Stires; Mary M Heckler; Xiaoyong Fu; Zhao Li; Catherine S Grasso; Michael J Quist; Joseph A Lewis; Uwe Klimach; Alan Zwart; Akanksha Mahajan; Balázs Győrffy; Luciane R Cavalli; Rebecca B Riggins
Journal:  Mol Cell Endocrinol       Date:  2017-09-19       Impact factor: 4.102

Review 9.  Higher order genomic organization and epigenetic control maintain cellular identity and prevent breast cancer.

Authors:  A J Fritz; N E Gillis; D L Gerrard; P D Rodriguez; D Hong; J T Rose; P N Ghule; E L Bolf; J A Gordon; C E Tye; J R Boyd; K M Tracy; J A Nickerson; A J van Wijnen; A N Imbalzano; J L Heath; S E Frietze; S K Zaidi; F E Carr; J B Lian; J L Stein; G S Stein
Journal:  Genes Chromosomes Cancer       Date:  2019-03-15       Impact factor: 5.006

10.  Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms.

Authors:  Koen Schipper; Anne Paulien Drenth; Eline van der Burg; Samuel Cornelissen; Sjoerd Klarenbeek; Micha Nethe; Jos Jonkers
Journal:  Cancer Res       Date:  2020-02-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.